Clinical Insights and Strategies to Improve NSCLC Care

Explore key issues in the management of advanced NSCLC in this educational program designed to keep you abreast of rapidly evolving treatment practices. Gain expert insights on new developments as they emerge with interactive modules short expert commentaries and an Interactive Decision Support Tool that will let you compare your treatment choices for specific patient scenarios in advanced NSCLC with those of 5 experts.

Share

Program Content

Activities

NSCLC: A Look Ahead
Immunotherapy and Targeted Therapy in NSCLC: Where Are We Going in 2018?
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: December 28, 2017

Managing <i>ALK</i>+ NSCLC
My Approach for Managing Patients With Progressive ALK-Positive NSCLC
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: January 22, 2018

New Nivolumab Dosing
A New Nivolumab Dosing Option for Our Patients With Advanced NSCLC
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: April 16, 2018

Lung Cancer at AACR 2018
First-line Therapy in NSCLC: What You Need to Know From AACR 2018
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: June 01, 2018

Progression After New ICI Options
New Immunotherapy Paradigms Earlier in NSCLC: What Comes After Progression?
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: July 26, 2018

<i>ALK</i>+ NSCLC: Brigatinib
My Thoughts on First-line Treatment for ALK-Positive NSCLC Today
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: October 24, 2018

Activities

Advanced NSCLC Management
Advanced NSCLC Management: A Resource for Clinicians
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: February 15, 2018

Activities

EGFR+/High PD-L1 NSCLC
Treating a Patient With Newly Diagnosed Metastatic EGFR Mutant–Positive NSCLC and High PD-L1 Expression
Multimedia
Congratulations: You achieved a completion on 04/09/2022

Released: May 29, 2018

PD-L1 for Progressive NSCLC
PD-L1 Testing in the Setting of Progressive NSCLC After Chemotherapy
Multimedia
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2018

PD-L1–Negative Lung Adenocarcinoma
Treating a Patient With Newly Diagnosed Metastatic Lung Adenocarcinoma and < 1% PD-L1 Expression
Multimedia
Congratulations: You achieved a completion on 04/09/2022

Released: August 07, 2018

PD-L1–Low Metastatic Squamous NSCLC
Treating a Patient With Newly Diagnosed Metastatic Squamous NSCLC and Low PD-L1 Expression
Multimedia
Congratulations: You achieved a completion on 04/09/2022

Released: August 21, 2018

Activities

Slides: Personalizing Therapy in NSCLC
Clinical Insights to Improve NSCLC Care: Expert Guidance on Personalizing Therapy in an Era of Rapidly Increasing Complexity
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2018

NSCLC Personalizing Therapy
Clinical Insights to Improve NSCLC Care: Expert Guidance on Personalizing Therapy in an Era of Rapidly Increasing Complexity
Multimedia
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2018

Activities

Individualizing Treatment for Adv NSCLC
Individualizing Treatment for Advanced NSCLC in the New Therapeutic Landscape
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: November 12, 2018

Activities

ICIs in Stage III NSCLC: Recent Data
Recent Data on Immune Checkpoint Inhibition After Chemoradiotherapy in Unresectable Stage III NSCLC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: October 31, 2018

Expires: October 30, 2019

Faculty

cover img faculity

Lyudmila Bazhenova, MD

Associate Clinical Professor of Medicine
Division of Hematology-Oncology
University of California, San Diego
Medical Director, UC San Diego Moores Cancer Center Infusion Center
San Diego, California

cover img faculity

Edward B. Garon, MD, MS

Professor of Medicine
Director of Thoracic Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California

cover img faculity

Matthew Gubens, MD, MS

Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

cover img faculity

Leora Horn, MD, MSc

Assistant Professor, Hematology Oncology/Medicine
Vanderbilt Ingram Cancer Center
Vanderbilt University
Nashville, Tennessee

cover img faculity

Heather J. Jackson, PhD, FNP-BC, NEA-BC, FAANP

Associate Professor
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University School of Nursing
Administrative Director of Advanced Practice
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

cover img faculity

Melissa L. Johnson, MD

Assistant Professor
Division of Hematology/Oncology
Robert H. Lurie Comprehensive Cancer Center 
Northwestern University
Assistant Attending
Divison of Hematology/Oncology
Northwestern Memorial Hospital
Chicago, Illinois

cover img faculity

Karen L. Reckamp, MD, MS

Associate Professor
Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, California

cover img faculity

Thomas Stinchcombe, MD

Medical Oncologist
Thoracic Oncology Program
Duke University Medical Center
Durham, North Carolina

Provided by

ProCE Banner

Supporters

This activity is supported by educational grants from

AstraZeneca

Bristol Myers Squibb

Celgene TEXT Only

Genentech TEXT Only

Lilly

Merck Oncology

Novartis Pharmaceuticals Corporation

Takeda Oncology